BDSX (Biodesix Inc) Gross Profitability

Official company branding of Biodesix Inc (BDSX)

Effective management at Biodesix, Inc. (BDSX) is successfully scaling the business while reducing operating expenses. Leadership in molecular lung diagnostics allows the company to rapidly identify mutations via blood, which is reflected in the gross margin level, where 81.20 is the current value of the metric. Multi-omic tests diversify risks, ensuring a steady stream of orders from oncology centers for therapy selection.

BDSX Biodesix Corp Gross Profitability (07/04/2022 - 11/20/2026)

Financial and market metric breakdowns for Biodesix Inc (BDSX)

- current quotes and average value forecast:
- business market valuation indicators:
Basic company analysis:BDSX - Biodesix
Brand item of Biodesix

The high clinical value of Biodesix, Inc. (BDSX) tests provides the company with pricing power, although Medicare limits constrain profit growth potential. Gross margin measures the portion of revenue minus direct production costs, allowing investors to assess operational efficiency and the risk of overpaying at the peak of profitability through an analysis of the gross margin chart.